IN2014DN10669A - - Google Patents

Info

Publication number
IN2014DN10669A
IN2014DN10669A IN10669DEN2014A IN2014DN10669A IN 2014DN10669 A IN2014DN10669 A IN 2014DN10669A IN 10669DEN2014 A IN10669DEN2014 A IN 10669DEN2014A IN 2014DN10669 A IN2014DN10669 A IN 2014DN10669A
Authority
IN
India
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
salt
Prior art date
Application number
Inventor
Edward Savory
Martyn Pritchard
Mike Ashwood
Original Assignee
Proximagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1211788.3A external-priority patent/GB201211788D0/en
Priority claimed from GBGB1304812.9A external-priority patent/GB201304812D0/en
Application filed by Proximagen Ltd filed Critical Proximagen Ltd
Publication of IN2014DN10669A publication Critical patent/IN2014DN10669A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Abstract

A compound of formula (I), or a pharmaceutically acceptable salt thereof: wherein Z1, Z2, and Z , Q, R2, A, and R1 are as defined in the claims.
IN10669DEN2014 2012-07-03 2013-07-03 IN2014DN10669A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1211788.3A GB201211788D0 (en) 2012-07-03 2012-07-03 Pro-drug compounds
GBGB1304812.9A GB201304812D0 (en) 2013-03-15 2013-03-15 Pro-drug compounds
PCT/GB2013/051767 WO2014006407A1 (en) 2012-07-03 2013-07-03 Pro-drug compounds

Publications (1)

Publication Number Publication Date
IN2014DN10669A true IN2014DN10669A (en) 2015-08-28

Family

ID=48782540

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10669DEN2014 IN2014DN10669A (en) 2012-07-03 2013-07-03

Country Status (7)

Country Link
US (2) US20140011773A1 (en)
EP (1) EP2870148A1 (en)
AU (1) AU2013285164A1 (en)
CA (1) CA2877578A1 (en)
IN (1) IN2014DN10669A (en)
WO (1) WO2014006407A1 (en)
ZA (1) ZA201409213B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2870148A1 (en) 2012-07-03 2015-05-13 Proximagen Limited Pro-drug compounds
GB201304814D0 (en) * 2013-03-15 2013-05-01 Proximagen Ltd Pro-drug compounds
GB201322934D0 (en) * 2013-12-23 2014-02-12 Proximagen Ltd Prodrug compounds
GB201322932D0 (en) * 2013-12-23 2014-02-12 Proximagen Ltd Pro-drug compounds
US10465188B2 (en) 2014-08-22 2019-11-05 Auckland Uniservices Limited Channel modulators
US11717506B2 (en) * 2019-05-07 2023-08-08 The Johns Hopkins University Neuroprotective compounds for amyotrophic lateral sclerosis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126311B1 (en) 1983-05-18 1989-09-13 Beecham Group Plc Benzopyran derivatives.
EP0139992B1 (en) 1983-09-01 1988-12-28 Beecham Group Plc Chromanol derivatives
EP0301713A3 (en) 1987-07-07 1990-05-02 Beecham Group Plc Chroman derivatives for treatment of pulmonary hypertension
PT673374E (en) 1992-12-11 2000-07-31 Smithkline Beecham Plc PHARMACEUTICAL COMPOSITIONS CONTAINING BICYCLE COMPOUNDS
KR100326968B1 (en) 1992-12-11 2002-07-27 스미스클라인비이참피이엘시이 Bicyclic Compounds with Pharmaceutical Activity
CZ292896B6 (en) 1994-02-04 2003-12-17 Smithkline Beecham P. L. C. Process for enantioselectively epoxidising and compounds suitable therefor as catalysts
CA2192480C (en) 1994-06-10 2007-07-24 Wai Ngor Chan Benzopyrans and their use as therapeutic agents
GB9411635D0 (en) 1994-06-10 1994-08-03 Smithkline Beecham Plc Novel treatment
GB9813949D0 (en) 1998-06-29 1998-08-26 Smithkline Beecham Plc Novel compounds
WO2006071995A1 (en) 2004-12-23 2006-07-06 Xenoport, Inc. Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
MX2010013313A (en) 2008-06-05 2011-05-30 Minster Res Ltd Novel treatments.
CA2726874A1 (en) 2008-06-05 2009-12-10 Minster Research Limited Novel treatments
CN102970991A (en) 2009-12-03 2013-03-13 普罗克西梅根有限公司 Treatment of allodynia and hyperalgesia
AU2010325755A1 (en) 2009-12-03 2012-06-21 Proximagen Ltd Treatment of infectious diseases
EP2870148A1 (en) 2012-07-03 2015-05-13 Proximagen Limited Pro-drug compounds
GB201304814D0 (en) 2013-03-15 2013-05-01 Proximagen Ltd Pro-drug compounds

Also Published As

Publication number Publication date
CA2877578A1 (en) 2014-01-09
AU2013285164A1 (en) 2015-01-22
US20150322034A1 (en) 2015-11-12
WO2014006407A1 (en) 2014-01-09
US20140011773A1 (en) 2014-01-09
ZA201409213B (en) 2016-07-27
US9499510B2 (en) 2016-11-22
EP2870148A1 (en) 2015-05-13

Similar Documents

Publication Publication Date Title
MX2015002040A (en) Deuterated baricitinib.
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
MX2015001246A (en) Deuterated ibrutinib.
PH12014502169A1 (en) N-cyclylamides as nematicides
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
MX2013012542A (en) Amide compound and pharmaceutical application therefor.
IN2015DN01035A (en)
TW201231056A (en) Metal salt compositions
UA118666C2 (en) Novel pyrazol derivatives
MY191628A (en) Novel triazolo[4,5-d]pyrimidine derivatives
MX2014012477A (en) Pyrrolopyrazone inhibitors of tankyrase.
MX2014002552A (en) Pyrazole compound and use thereof for medical purposes.
MX2014014832A (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase.
JOP20130342B1 (en) A stabilized pemetrexed formulation
MY182328A (en) Pyridine-2-amides useful as cb2 agonists
PH12015501088A1 (en) Dimeric compounds
MX346248B (en) [1, 2, 3]triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 agonists.
MX349373B (en) Novel pyrazine derivatives.
PH12015502178A1 (en) Pyridinylpyrazoloquinoline compound
IN2014DN10669A (en)
IN2014DN07996A (en)
MX2015008829A (en) Deuterated momelotinib.
PH12015501146A1 (en) Hydantoin derivative
PH12015500399A1 (en) Azaindolines
MX2015016766A (en) Novel tetrazolone derivatives.